Summit Therapeutics Inc.SMMTNASDAQ
LOADING
|||
Switch Symbol:
Gross Profit Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
-13.51%
↑ 99% above average
Average (39q)
-1692.68%
Historical baseline
Range
High:4330.77%
Low:-74603.74%
CAGR
-2.2%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -13.51% |
| Q2 2025 | -48.00% |
| Q1 2025 | 99.83% |
| Q4 2024 | -74603.74% |
| Q3 2024 | 0.01% |
| Q2 2024 | 25.93% |
| Q1 2024 | 96.79% |
| Q4 2023 | -40.23% |
| Q3 2023 | -153.81% |
| Q2 2023 | 0.00% |
| Q1 2023 | 100.00% |
| Q4 2022 | -370.45% |
| Q3 2022 | 13.96% |
| Q2 2022 | -22.78% |
| Q1 2022 | -0.40% |
| Q4 2021 | -80.83% |
| Q3 2021 | 2196.49% |
| Q2 2021 | -70.31% |
| Q1 2021 | 3.78% |
| Q4 2020 | 2.21% |
| Q3 2020 | 6.47% |
| Q2 2020 | -55.99% |
| Q1 2020 | 253.29% |
| Q4 2019 | -257.53% |
| Q4 2019 | 30.22% |
| Q3 2019 | -74.88% |
| Q2 2019 | -42.98% |
| Q1 2019 | 0.00% |
| Q4 2018 | -98.28% |
| Q3 2018 | 834.68% |
| Q2 2018 | 133.74% |
| Q1 2018 | -30.85% |
| Q4 2017 | -30.53% |
| Q3 2017 | 174.88% |
| Q2 2017 | 145.68% |
| Q1 2017 | 22.11% |
| Q4 2016 | 4330.77% |
| Q3 2016 | -77.97% |
| Q2 2016 | -73.54% |
| Q1 2016 | -31.60% |